english Archives - 29 중 5 번째 페이지

Jay Y. Lee Acquitted After Decade-Long Trial, Renewing Focus on Samsung’s Bio Strategy

Jay Y. Lee, Chairman of Samsung Electronics. [Photo = Yonhap News] Samsung Electronics Chairman Jay Y. Lee has been cleared of all charges related to the controversial merger and accounting…

Cheon Okhyeon

2025-07-17

Alteogen May Qualify for KOSPI…Management Holds the Key

[photo=Alteogen] Will Alteogen, a South Korean biopharmaceutical company, make the leap from KOSDAQ to KOSPI? The question has gained traction after Hyeong In-woo, the company's second-largest shareholder and CEO of…

Cheon Okhyeon

2025-07-10

PharmaResearch Scraps Spin-Off Plan, Investors Cheer

PharmaResearch, a South Korean regenerative medicine company, has decided to scrap its planned spin-off, reversing course amid mounting shareholder opposition. The company had previously proposed a transition to a holding…

Cheon Okhyeon

2025-07-08

“Beyond Biosimilars”…Celltrion Moves into New Drug Development

Celltrion is accelerating its transition from a biosimilar-focused strategy to full-scale new drug development. With successive approvals for clinical trial applications (INDs) in Korea and abroad, the company is rapidly…

Cheon Okhyeon

2025-07-07

LigaChemBio Aims to Secure 20 ADC Pipeline Assets by 2027

LigaChemBio has announced its plan to build a pipeline of 20 antibody-drug conjugate (ADC) assets by 2027. The company intends to accelerate global commercialization by expanding clinical-stage programs while actively…

Cheon Okhyeon

2025-07-01

Celltrion to Buy Back KRW 100 Billion in Treasury Shares

Celltrion announced on June 26 that its board of directors has approved an additional repurchase of treasury shares worth approximately KRW 100 billion (USD 72 million). The repurchase will be…

Cheon Okhyeon

2025-06-26

Pharos’ AI-Designed Leukemia Drug Earns Orphan Designation in Europe

Pharos iBio, a South Korea-based biotech specializing in AI-driven drug discovery, announced that its lead investigational asset PHI-101, a next-generation therapy for acute myeloid leukemia (AML), has been granted orphan…

Won Jonghyuck

2025-06-24

Hanmi Pharmaceutical reveals Phase 1 results for triple agonist obesity drug HM15275

Hanmi Pharmaceutical has released the first clinical data from its next-generation triple agonist obesity drug, HM15275, showing promising early efficacy with a differentiated approach to muscle-sparing weight loss. At the…

Cheon Okhyeon

2025-06-23

Lotte Biologics Signs CMO Agreement with UK Biotech Firm ‘OTTIMO’

Lotte Biologics has signed a contract manufacturing organization (CMO) agreement with UK-based biotech company OTTIMO Pharma for the production of an antibody drug substance. According to Lotte Biologics on the…

Cheon Okhyeon

2025-06-19

Mini Organs Instead of Mice? Samsung Biologics Joins the Organoid Revolution

The era of developing new drugs without animal testing is becoming a reality. As the U.S. Food and Drug Administration (FDA) moves to phase out mandatory animal testing, “organoids”—also known…

Cheon Okhyeon

2025-06-16